Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq' Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025
4 mins read . Sep 5, 2025

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025
3 mins read . Aug 20, 2025

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025
8 mins read . Aug 18, 2025

Explore our products
Unlimited Trading starting at ₹249 ₹0
Open Trading Account
Recent Article
- •
- •
- •
- •